Veno Finance USD Price & Performance (VNOUSD)

Lawrence J. Jasinski, a director at LeMaitre Vascular, sold 3,142 shares valued at $289,064, reducing his holdings to 2,607 shares. This comes as the company navigates market fluctuations, with its stock down 13% in a week, despite strong Q4 earnings and a $300 million cash reserve for strategic expansions.1

Trent G. Kamke, an insider at LeMaitre Vascular, sold 2,009 shares for $164,979, marking a 26.53% reduction in his holdings. The stock, recently trading at $81.91, has seen fluctuations despite a dividend increase and analysts' mixed ratings, highlighting challenges in sustaining its valuation.2

Raymond James Financial acquired 161,708 shares of LeMaitre Vascular, signaling confidence in the company’s prospects. Despite recent insider sales and volatile stock performance, institutional interest suggests optimism about its long-term growth and strategic initiatives in the competitive vascular device market.3